BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 17707198)

  • 1. Intensity modulated radiotherapy improves target coverage and parotid gland sparing when delivering total mucosal irradiation in patients with squamous cell carcinoma of head and neck of unknown primary site.
    Bhide S; Clark C; Harrington K; Nutting CM
    Med Dosim; 2007; 32(3):188-95. PubMed ID: 17707198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Helical tomotherapy for head and neck squamous cell carcinoma: dosimetric comparison with linear accelerator-based step-and-shoot IMRT.
    Murthy V; Master Z; Gupta T; Ghosh-Laskar S; Budrukkar A; Phurailatpam R; Agarwal J
    J Cancer Res Ther; 2010; 6(2):194-8. PubMed ID: 20622367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensity-modulated radiotherapy improves target coverage, spinal cord sparing and allows dose escalation in patients with locally advanced cancer of the larynx.
    Clark CH; Bidmead AM; Mubata CD; Harrington KJ; Nutting CM
    Radiother Oncol; 2004 Feb; 70(2):189-98. PubMed ID: 15028407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity- modulated radiotherapy (IMRT) for head-and-neck cancer.
    Parliament MB; Scrimger RA; Anderson SG; Kurien EC; Thompson HK; Field GC; Hanson J
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):663-73. PubMed ID: 14967418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sparing the parotid glands and surgically transferred submandibular gland with helical tomotherapy in post-operative radiation of head and neck cancer: a planning study.
    Saibishkumar EP; Jha N; Scrimger RA; MacKenzie MA; Daly H; Field C; Fallone G; Parliament MB
    Radiother Oncol; 2007 Oct; 85(1):98-104. PubMed ID: 17923162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Target volume definition for head and neck intensity modulated radiotherapy: pre-clinical evaluation of PARSPORT trial guidelines.
    Guerrero Urbano MT; Clark CH; Kong C; Miles E; Dearnaley DP; Harrington KJ; Nutting CM; PARSPORT Trial Management Group
    Clin Oncol (R Coll Radiol); 2007 Oct; 19(8):604-13. PubMed ID: 17706404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reducing the risk of xerostomia and mandibular osteoradionecrosis: the potential benefits of intensity modulated radiotherapy in advanced oral cavity carcinoma.
    Ahmed M; Hansen VN; Harrington KJ; Nutting CM
    Med Dosim; 2009; 34(3):217-24. PubMed ID: 19647632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing 3DCRT and inversely optimized IMRT planning for head and neck cancer: equivalence between step-and-shoot and sliding window techniques.
    Longobardi B; De Martin E; Fiorino C; Dell'oca I; Broggi S; Cattaneo GM; Calandrino R
    Radiother Oncol; 2005 Nov; 77(2):148-56. PubMed ID: 16260056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
    Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic intensity-modulated non-coplanar arc radiotherapy (INCA) for head and neck cancer.
    Krayenbuehl J; Davis JB; Ciernik IF
    Radiother Oncol; 2006 Nov; 81(2):151-7. PubMed ID: 17055095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program.
    Vergeer MR; Doornaert PA; Rietveld DH; Leemans CR; Slotman BJ; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2009 May; 74(1):1-8. PubMed ID: 19111400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of patterns of failure and subjective salivary function in patients treated with intensity modulated radiotherapy for head and neck squamous cell carcinoma.
    Daly ME; Lieskovsky Y; Pawlicki T; Yau J; Pinto H; Kaplan M; Fee WE; Koong A; Goffinet DR; Xing L; Le QT
    Head Neck; 2007 Mar; 29(3):211-20. PubMed ID: 17111429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significant improvement in normal tissue sparing and target coverage for head and neck cancer by means of helical tomotherapy.
    Fiorino C; Dell'Oca I; Pierelli A; Broggi S; De Martin E; Di Muzio N; Longobardi B; Fazio F; Calandrino R
    Radiother Oncol; 2006 Mar; 78(3):276-82. PubMed ID: 16546279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensity-modulated radiotherapy for head and neck cancer.
    Caglar HB; Allen AM
    Clin Adv Hematol Oncol; 2007 Jun; 5(6):425-31. PubMed ID: 17679916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of the initial volume of parotid glands in xerostomia for patients with head and neck cancers treated with IMRT.
    Nishimura Y; Nakamatsu K; Shibata T; Kanamori S; Koike R; Okumura M; Suzuki M
    Jpn J Clin Oncol; 2005 Jul; 35(7):375-9. PubMed ID: 15976068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrences after conformal parotid-sparing radiotherapy for head and neck cancer.
    Bussels B; Maes A; Hermans R; Nuyts S; Weltens C; Van den Bogaert W
    Radiother Oncol; 2004 Aug; 72(2):119-27. PubMed ID: 15297131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of salivary gland dosimetry on post-IMRT recovery of saliva output and xerostomia grade for head-and-neck cancer patients treated with or without contralateral submandibular gland sparing: a longitudinal study.
    Wang ZH; Yan C; Zhang ZY; Zhang CP; Hu HS; Tu WY; Kirwan J; Mendenhall WM
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1479-87. PubMed ID: 20934262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conformal and intensity modulated irradiation of head and neck cancer: the potential for improved target irradiation, salivary gland function, and quality of life.
    Eisbruch A; Dawson LA; Kim HM; Bradford CR; Terrell JE; Chepeha DB; Teknos TN; Anzai Y; Marsh LH; Martel MK; Ten Haken RK; Wolf GT; Ship JA
    Acta Otorhinolaryngol Belg; 1999; 53(3):271-5. PubMed ID: 10635407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacy.
    Klem ML; Mechalakos JG; Wolden SL; Zelefsky MJ; Singh B; Kraus D; Shaha A; Shah J; Pfister DG; Lee NY
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1100-7. PubMed ID: 17980501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Volumetric modulated arc radiotherapy for carcinomas of the oro-pharynx, hypo-pharynx and larynx: a treatment planning comparison with fixed field IMRT.
    Vanetti E; Clivio A; Nicolini G; Fogliata A; Ghosh-Laskar S; Agarwal JP; Upreti RR; Budrukkar A; Murthy V; Deshpande DD; Shrivastava SK; Dinshaw KA; Cozzi L
    Radiother Oncol; 2009 Jul; 92(1):111-7. PubMed ID: 19157609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.